Ultrasound-guided Versus Arthroscopic Guided PRF Injection for TMJ Disc Displacement.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ultrasound guided platelet rich fibrin injection, Arthroscopic guided platelet rich Fibrin injection.
- Who it may be relevant to
- Registry conditions: TMJ Disc Displacement With Reduction. Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Ultrasound Guided Versus Arthroscopic Guided PRF Injection in Management of Temporomandibular Joint Disc Displacement With Reduction: A Randomized Controlled Clinical Trials
Overview
To compare the clinical effectiveness of ultrasound-guided versus arthroscopic guided platelet rich fibrin injection in the management of anterior disc displacement with reduction of the temporomandibular joint, in terms of pain reduction, improvement of mandibular function, and patient-reported outcomes.
Detailed description
Internal derangements of the temporomandibular joint, particularly disc displacement with reduction, represent a significant proportion of temporomandibular disorders. Conventional conservative treatments may not always achieve satisfactory symptom resolution, leading to increased interest in minimally invasive interventions. PRF has gained attention for its ability to promote tissue regeneration, reduce inflammation, and enhance healing through the sustained release of growth factors. Image-guided injection techniques are essential for ensuring accurate delivery of PRF into the targeted joint structures. Arthroscopic-guided injection allows direct visualization of intra-articular anatomy but is invasive, technically demanding, and associated with higher cost and procedural complexity. In contrast, ultrasound-guided injection is a non-invasive, radiation-free, and cost- effective technique that enables real-time visualization of soft tissues and needle placement. Despite these advantages, the comparative clinical efficacy of ultrasound-guided versus arthroscopic-guided PRF injection remains inadequately explored, particularly in patients with TMJ disc displacement with reduction.
Interventions
- Device ultrasound guided platelet rich fibrin injection
1. A high-frequency linear ultrasound probe will be used to identify the TMJ space. 2. A sterile syringe containing 1 mL of PRF will be inserted into the superior joint space under real-time ultrasound guidance. 3. PRF will be injected slowly with continuous confirmation of needle position. - Device Arthroscopic guided platelet rich Fibrin injection
1. TMJ arthroscopy will be performed under local or general anesthesia following standard aseptic preparation. 2. The superior joint space will be visualized using a 1.9 mm arthroscope. 3. A sterile syringe containing 1 mL of PRF will be introduced through a lateral portal under direct arthroscopic visualization. 4. PRF will be injected slowly into the superior joint space.
Primary outcome measures
- Maximum mouth opening [Time frame: 6 months]
Secondary outcome measures (1)
- Pain intensity [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Patients aged 18-60 years.
- Clinically and radiographically diagnosed temporomandibular joint disc displacemet with reduction.
- Presence of TMJ pain exacerbated by mandibular movement.
- Limited mandibular function and/or reduced maximum mouth opening.
- Symptoms persisting for at least 3 months.
- Failure of conservative treatment (e.g. occlusal splint, physiotherapy, NSAIDs). -Ability to understand the study protocol and provide informed consent.
Exclusion criteria
- Previous TMJ surgery or arthroscopic intervention.
- Intra-articular injection in the TMJ within the last 6 months.
- Systemic inflammatory or autoimmune joint diseases.
- Coagulation disorders or current anticoagulant therapy.
- Active local infection at the injection site.
- Pregnancy or lactation.
- Severe degenerative joint disease (advanced osteoarthritis).
- Known allergy or contraindication to ( PRF) preparation.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Gonzalez LV, Lopez JP, Diaz-Baez D, Orjuela MP, Chavez M. Clinical outcomes of operative arthroscopy and temporomandibular medical infiltration with platelet-rich fibrin in upper and lower articular space. J Craniomaxillofac Surg. 2021 Dec;49(12):1162-1168. doi: 10.1016/j.jcms.2021.07.001. Epub 2021 Aug 3. PMID 34384651
- Chaudhary FA, Ahmad B, Butt DQ, Hameed S, Bashir U. Normal range of maximum mouth opening in Pakistani population: A cross-sectional study. J Int Oral Health. 2019;11(6):353-356. doi:10.4103/jioh.jioh_127_19.
Identifiers
NCT: NCT07535073 · OMFS-TMJ-PRF-RCT01